References from scientific journals

Bevacizumab (Avastin) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Garcia J, et al. Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26. Cancer Treat Rev. 2020. PMID: 32335505 Free article. Review.

When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. ...This review provides an overview of the clinical experi …
When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin) entered clinical practice more than 15 years ago, it was o …

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.

Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bamias A, et al. Ann Oncol. 2017 Aug 1;28(8):1842-1848. doi: 10.1093/annonc/mdx228. Ann Oncol. 2017. PMID: 28481967 Free article. Clinical Trial.

The tolerability of bevacizumab was similar with administration upfront or after PD. CONCLUSIONS: Post-PD bevacizumab use may have confounded OS results in AURELIA. In these exploratory analyses of non-randomized subgroups, bevacizumab use, either with chemot …
The tolerability of bevacizumab was similar with administration upfront or after PD. CONCLUSIONS: Post-PD bevacizumab use may …

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Li M, Kroetz DL. Li M, et al. Pharmacol Ther. 2018 Feb;182:152-160. doi: 10.1016/j.pharmthera.2017.08.012. Epub 2017 Sep 4. Pharmacol Ther. 2018. PMID: 28882537 Free PMC article. Review.

Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment a …
Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovas …

The role of bevacizumab in the treatment of glioblastoma.

Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. Diaz RJ, et al. J Neurooncol. 2017 Jul;133(3):455-467. doi: 10.1007/s11060-017-2477-x. Epub 2017 May 19. J Neurooncol. 2017. PMID: 28527008 Review.

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. ...The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. ...
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009 …

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Rosen LS, Jacobs IA, Burkes RL. Rosen LS, et al. Target Oncol. 2017 Oct;12(5):599-610. doi: 10.1007/s11523-017-0518-1. Target Oncol. 2017. PMID: 28801849 Free PMC article. Review.

High-quality, safe, and effective biosimilars have the potential to expand access to bevacizumab. Most of the bevacizumab biosimilars currently in development are in clinical trials in patients with non-small-cell lung cancer, and future authorization for mCRC indic …
High-quality, safe, and effective biosimilars have the potential to expand access to bevacizumab. Most of the bevacizumab bios …

Review of neovascular age-related macular degeneration treatment options.

Holekamp NM. Holekamp NM. Am J Manag Care. 2019 Jul;25(10 Suppl):S172-S181. Am J Manag Care. 2019. PMID: 31419088 Free article. Review.


Bevacizumab in ovarian cancer: A critical review of phase III studies.

Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Rossi L, et al. Oncotarget. 2017 Feb 14;8(7):12389-12405. doi: 10.18632/oncotarget.13310. Oncotarget. 2017. PMID: 27852039 Free PMC article. Review.

Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). ...Furthermore, BV effectively improved the quality of life with regard to abd …
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-target …

Bevacizumab in advanced lung cancer: state of the art.

Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Assoun S, et al. Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 Aug 16. Future Oncol. 2017. PMID: 28812378 Review.

In the years to come, bevacizumab might be associated with new molecular therapies or immuno-oncology drugs, in order to optimize response rates and overcome resistances. This review summarizes the pharmacologic properties, clinical efficacy and safety of bevacizumab …
In the years to come, bevacizumab might be associated with new molecular therapies or immuno-oncology drugs, in order to optimize res …

Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.

Gao F, Yang C. Gao F, et al. Curr Cancer Drug Targets. 2020;20(1):3-18. doi: 10.2174/1568009619666191114110359. Curr Cancer Drug Targets. 2020. PMID: 31729943 Review.

Currently, two monoclonal antibodies, anti-VEGF-A antibody Bevacizumab and anti-VEGFR2 antibody Ramucizumab, have been approved for the treatment of solid tumors. ...On this basis, a number of clinical studies have been performed to investigate the therapeutic potential of …
Currently, two monoclonal antibodies, anti-VEGF-A antibody Bevacizumab and anti-VEGFR2 antibody Ramucizumab, have been approved for t …

Using intravitreal bevacizumab (Avastin()) - Indian Scenario.

Kumar A, Ravani R. Kumar A, et al. Indian J Ophthalmol. 2017 Jul;65(7):545-548. doi: 10.4103/ijo.IJO_431_17. Indian J Ophthalmol. 2017. PMID: 28724808 Free PMC article. No abstract available.